CL2025002035A1 - Compuestos moduladores de receptores de dopamina d3/d2 - Google Patents
Compuestos moduladores de receptores de dopamina d3/d2Info
- Publication number
- CL2025002035A1 CL2025002035A1 CL2025002035A CL2025002035A CL2025002035A1 CL 2025002035 A1 CL2025002035 A1 CL 2025002035A1 CL 2025002035 A CL2025002035 A CL 2025002035A CL 2025002035 A CL2025002035 A CL 2025002035A CL 2025002035 A1 CL2025002035 A1 CL 2025002035A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- receptors
- modulate dopamine
- formula
- dopamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363479530P | 2023-01-11 | 2023-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2025002035A1 true CL2025002035A1 (es) | 2025-10-03 |
Family
ID=89573273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025002035A CL2025002035A1 (es) | 2023-01-11 | 2025-07-09 | Compuestos moduladores de receptores de dopamina d3/d2 |
| CL2026000558A CL2026000558A1 (es) | 2023-01-11 | 2026-02-25 | Compuestos moduladores de receptores de dopamina d3/d2 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2026000558A CL2026000558A1 (es) | 2023-01-11 | 2026-02-25 | Compuestos moduladores de receptores de dopamina d3/d2 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12168007B1 (enExample) |
| EP (1) | EP4400495A1 (enExample) |
| JP (2) | JP7686096B2 (enExample) |
| KR (2) | KR102921799B1 (enExample) |
| CN (2) | CN122427144A (enExample) |
| AR (1) | AR131577A1 (enExample) |
| AU (1) | AU2024208533A1 (enExample) |
| CL (2) | CL2025002035A1 (enExample) |
| CO (1) | CO2025010725A2 (enExample) |
| GE (1) | GEAP202516807A (enExample) |
| IL (1) | IL321654A (enExample) |
| JO (1) | JOP20250164A1 (enExample) |
| MX (1) | MX2025008101A (enExample) |
| PE (1) | PE20260287A1 (enExample) |
| TW (1) | TW202432139A (enExample) |
| WO (1) | WO2024150068A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026153547A1 (zh) * | 2025-01-20 | 2026-07-23 | 上海则正医药科技股份有限公司 | D3/d2受体部分激动剂及制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227534B1 (en) | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
| EP1870405A1 (en) | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
| JP5732453B2 (ja) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Ｎｈ酸性化合物のプロドラッグ |
| WO2020156312A1 (zh) | 2019-01-30 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
| US12617759B2 (en) | 2019-10-29 | 2026-05-05 | Shanghai Hansoh Biomedical Co., Ltd. | Modifier of four-membered ring derivative, preparation method and application thereof |
| KR102947882B1 (ko) | 2019-11-05 | 2026-04-03 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 벤조티오펜 유도체 조절제, 그의 제조 방법 및 그의 용도 |
-
2024
- 2024-01-08 KR KR1020240002897A patent/KR102921799B1/ko active Active
- 2024-01-09 AR ARP240100045A patent/AR131577A1/es unknown
- 2024-01-10 US US18/409,478 patent/US12168007B1/en active Active
- 2024-01-10 IL IL321654A patent/IL321654A/en unknown
- 2024-01-10 AU AU2024208533A patent/AU2024208533A1/en active Pending
- 2024-01-10 GE GEAP202516807A patent/GEAP202516807A/en unknown
- 2024-01-10 TW TW113101017A patent/TW202432139A/zh unknown
- 2024-01-10 WO PCT/IB2024/000026 patent/WO2024150068A2/en not_active Ceased
- 2024-01-10 CN CN202610307661.1A patent/CN122427144A/zh active Pending
- 2024-01-10 PE PE2025001450A patent/PE20260287A1/es unknown
- 2024-01-10 EP EP24151077.5A patent/EP4400495A1/en active Pending
- 2024-01-10 JP JP2024001696A patent/JP7686096B2/ja active Active
- 2024-01-10 CN CN202480007498.6A patent/CN120569367A/zh active Pending
- 2024-10-29 US US18/930,023 patent/US20250049786A1/en active Pending
-
2025
- 2025-05-19 JP JP2025083110A patent/JP2025122072A/ja active Pending
- 2025-07-09 CL CL2025002035A patent/CL2025002035A1/es unknown
- 2025-07-10 MX MX2025008101A patent/MX2025008101A/es unknown
- 2025-07-10 JO JOJO/P/2025/0164A patent/JOP20250164A1/ar unknown
- 2025-08-05 CO CONC2025/0010725A patent/CO2025010725A2/es unknown
-
2026
- 2026-01-29 KR KR1020260017571A patent/KR20260019592A/ko active Pending
- 2026-02-25 CL CL2026000558A patent/CL2026000558A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN120569367A (zh) | 2025-08-29 |
| EP4400495A1 (en) | 2024-07-17 |
| CO2025010725A2 (es) | 2025-08-29 |
| KR102921799B1 (ko) | 2026-02-04 |
| JP2024098972A (ja) | 2024-07-24 |
| PE20260287A1 (es) | 2026-02-10 |
| US12168007B1 (en) | 2024-12-17 |
| TW202432139A (zh) | 2024-08-16 |
| US20250049786A1 (en) | 2025-02-13 |
| KR20260019592A (ko) | 2026-02-10 |
| WO2024150068A3 (en) | 2024-08-22 |
| GEAP202516807A (en) | 2025-08-25 |
| AU2024208533A1 (en) | 2025-07-10 |
| AR131577A1 (es) | 2025-04-09 |
| JP7686096B2 (ja) | 2025-05-30 |
| JP2025122072A (ja) | 2025-08-20 |
| MX2025008101A (es) | 2025-08-01 |
| CL2026000558A1 (es) | 2026-06-05 |
| JOP20250164A1 (ar) | 2025-07-10 |
| IL321654A (en) | 2025-08-01 |
| KR20240112213A (ko) | 2024-07-18 |
| WO2024150068A2 (en) | 2024-07-18 |
| CN122427144A (zh) | 2026-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017009891A2 (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| PY1996328A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| CO2018011064A2 (es) | Inhibidores de bromodominios | |
| CL2019001264A1 (es) | Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v. | |
| UY27884A1 (es) | Moduladores del receptor de glucocorticoides | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| CO2020014677A2 (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes | |
| UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| CL2021001461A1 (es) | Moduladores de trex1 | |
| CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
| MX2021003945A (es) | Compuestos de indolinona para uso como inhibidores de map4k1. | |
| NZ713589A (en) | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level | |
| ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| CO2021013166A2 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| ECSP088966A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| CL2018001631A1 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| CR20220299A (es) | Derivados de becimidazol | |
| CO2025010725A2 (es) | Compuestos moduladores de receptores de dopamina d3/d2 | |
| MX2021002260A (es) | Compuestos utiles como moduladores de la autofagia mediada por chaperonas. | |
| DOP2024000165A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| CU24543B1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| CO2024006398A2 (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| CL2023003168A1 (es) | Moduladores de trex1 | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 |